Caris Life Sciences, Inc. · NASDAQ:CAI
Caris Life Sciences — Q4 2025 Earnings Presentation
15 slides from Caris Life Sciences's earnings presentation, Feb 26, 2026
Slide 1: Where Molecular Science Meets Artificial Intelligence
Where Molecular Science Meets Artificial Intelligence Q4 2025 Earnings Call February 26, 2026
Slide 2: Important Information and Disclaimer
Important Information and Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in t
Slide 3: Powerful Molecular Platform
Powerful Molecular Platform MI Profile Caris Assure AI & Dataset Precision Oncology Drug Discovery & Multi-Modal, Clinico- Alliance (POA) Data Analytics Tissue-Based Blood-Based Genomic Dataset Research, Data & Clinical Data & AI-Enabled Platform Platform Leveraging AI/ML at Scale Trials Collaborati
Slide 4: Strong Revenue Performance for Q4 2025 and FY 2025
Strong Revenue Performance for Q425 and FY 2025 Total Q4 Revenue Full Year Revenue ($ in millions) ($ in millions) Pharma R&D Services $292.9 (2) Pharma R&D Services $812.0 (2) Molecular Profiling Services $10.8 Molecular Profiling Services $45.3 97%(1) 125%(1) $412.3 $129.9 $282.1 $63.1 $766.7 $35.
Slide 5: Q4 2025 Performance Highlights
Q4 2025 Performance Highlights GAAP Revenue growth of 125% - from $130MM to $293MM (inclusive of $89.8m additional revenue from exceeding accrual on prior period cases) Volume growth of 20% - completing 52,700 clinical cases Clinical ASP increase of 150% - from $2,146 to $5,357 (inclusive of $
Slide 6: Molecular Profiling Growth Driven by Volume and ASP Uplift
Molecular Profiling Growth Driven by Volume and ASP Uplift Molecular Profiling Services Revenue Molecular Profiling Services Volume (2) ($ in millions) $766.7(1) Blood 199,300 Blood Tissue 162,900 22% 29,000 Tissue $81.1 16,300 170,300 146,600 120% FY 2024 FY 2025 $349.1 $685.6 Molecular Profiling S
Slide 7: Technology Differentiation and Commercial Execution Driving Clinical Volume Growth
Technology Differentiation and Commercial Execution Driving Clinical Volume Growth Performance Drivers Total Clinical Volume Strong performance across therapy selection with growth rate of 20%, improving from Q325 of 18% 20% +22% YoY Q4 FY25 YoY Growth FY25 Continued traction with Caris Assure,
Slide 8: Caris Detect - Multi-Cancer Early Detection (MCED) Whole Genome - Achieve 1 Interim Readout
Caris Detect - Multi-Cancer Early Detection (MCED) Whole Genome - Achieve 1 Interim Readout Achieve 1 Interim Readout Summary 100% 99.1% 99.1% Achieve 1 95.3% Interim Readout 2,122 samples split approximately 30% 75% 77.1% cancer, 70% undiagnosed Undiagnosed subjects had screening or symptomatic
Slide 9: Caris Assure For Multi-Cancer Early Detection (MCED) Achieve 1 Interim Readout by Cancer Type
Caris Assure For Multi-Cancer Early Detection (MCED) Achieve 1 Interim Readout by Cancer Type Achieve 1 Interim Readout Stage I & II Sensitivity by Cancer Type (n=403) Breast (n 253) 53% Bowel (n 45) 62% Prostate (n 38) 79% Uterus (n 19) 74% Lung (n 15) 87% Pancreas (n 7) 71% Head and Neck (n 7) 100
Slide 10: Additional Pipeline Solutions - Status
Additional Pipeline Solutions - Status TUMOR NAIVE TUMOR INFORMED WHOLE GENOME WHOLE EXOME WHOLE EXOME WHOLE GENOME WHOLE TRANSCRIPTOME WHOLE TRANSCRIPTOME WHOLE TRANSCRIPTOME Therapy Selection for the following: Breast cancer patients who are: MRD intended use: Intended use: PATIENT POPULATION • Ac
Slide 11: Q4 2025 and FY 2025 Financial Overview
Q4 2025 and FY 2025 Financial Overview Q4 2024 Q4 2025 % Growth FY 2024 FY 2025 % Growth Total Revenue $130MM $293MM 125% $412MM $812MM 97% Molecular Profiling Revenue $94MM $282MM 199% $349MM $767MM 120% Pharma R&D Services Revenue $35MM $11MM -70% $63MM $45MM -28% Gross Margin(1) 54% 75% 21% 43% 6
Slide 12: Molecular Profiling Services Performance in FY25
Molecular Profiling Services Performance in FY25 Molecular Profiling Services Revenue: ($ in millions) MI Profile ASP $3,876 per case for 2025 cases Reported per financials Additional revenue from exceeding accrual on prior years cases Additional revenue from exceeding accrual on current year cases
Slide 13: Molecular Profiling Services Tailwinds
Molecular Profiling Services Tailwinds MI Profile ASP Benefitted from launch of MI Cancer Seek and sequential improvement throughout Molecular Profiling Services Gross Margin Expansion (1) FY2025, supported based on contracting and payer collection experience leading to favorable additional cash col
Slide 14: Initiating Full Year 2026 Guidance
Initiating Full Year 2026 Guidance Total Revenue $1.00BN – $1.02BN Full year 2026 revenue is expected to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to full 23% – 26% YoY year 2025. Molecular profiling revenue is expected to grow approxi
Slide 15: Mission
Mission Caris was founded to make precision medicine a reality. We aim to fundamentally change the way disease is characterized and treated. We believe that more information is more power. And our philosophy is to provide every patient more power in the battle against disease.